Dechra Pharmaceuticals PLC Valuation
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
At this time, the firm appears to be overvalued. Dechra Pharmaceuticals shows a prevailing Real Value of $76.6 per share. The current price of the firm is $93.78. Our model computes the value of Dechra Pharmaceuticals from reviewing the firm fundamentals such as Profit Margin of 0.09 %, operating margin of 0.14 %, and Current Valuation of 4.04 B as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Dechra Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Dechra Pharmaceuticals is based on 3 months time horizon. Increasing Dechra Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dechra Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dechra Pink Sheet. However, Dechra Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 93.78 | Real 76.6 | Hype 93.78 | Naive 93.72 |
The intrinsic value of Dechra Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dechra Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dechra Pharmaceuticals PLC helps investors to forecast how Dechra pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dechra Pharmaceuticals more accurately as focusing exclusively on Dechra Pharmaceuticals' fundamentals will not take into account other important factors: Dechra Pharmaceuticals Total Value Analysis
Dechra Pharmaceuticals PLC is currently forecasted to have takeover price of 4.04 B with market capitalization of 4.3 B, debt of 313.7 M, and cash on hands of 123.7 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Dechra Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.04 B | 4.3 B | 313.7 M | 123.7 M |
Dechra Pharmaceuticals Investor Information
The book value of the company was currently reported as 12.3. The company last dividend was issued on the 27th of October 2022. Based on the key indicators related to Dechra Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Dechra Pharmaceuticals PLC is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Dechra Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Dechra Pharmaceuticals has an asset utilization ratio of 52.72 percent. This suggests that the Company is making $0.53 for each dollar of assets. An increasing asset utilization means that Dechra Pharmaceuticals PLC is more efficient with each dollar of assets it utilizes for everyday operations.Dechra Pharmaceuticals Ownership Allocation
Dechra Pharmaceuticals holds a total of 56.92 Million outstanding shares. Roughly 99.91 percent of Dechra Pharmaceuticals outstanding shares are held by general public with 0.09 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Dechra Pharmaceuticals Profitability Analysis
The company reported the revenue of 681.8 M. Net Income was 58.2 M with profit before overhead, payroll, taxes, and interest of 384.8 M.Dechra Pharmaceuticals Past Distributions to stockholders
About Dechra Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Dechra Pharmaceuticals. We calculate exposure to Dechra Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dechra Pharmaceuticals's related companies.Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. Dechra Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 1699 people.
8 Steps to conduct Dechra Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Dechra Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Dechra Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Dechra Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Dechra Pharmaceuticals' revenue streams: Identify Dechra Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Dechra Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Dechra Pharmaceuticals' growth potential: Evaluate Dechra Pharmaceuticals' management, business model, and growth potential.
- Determine Dechra Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Dechra Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
A single share of Dechra Pharmaceuticals represents a small ownership stake in the entity. As a stockholder of Dechra, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Dechra Pharmaceuticals Dividends Analysis For Valuation
Please note that Dechra Pharmaceuticals has scaled down on payment of dividends at this time.
There are various types of dividends Dechra Pharmaceuticals can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Dechra shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Dechra Pharmaceuticals PLC directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Dechra pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Dechra Pharmaceuticals by the value of the dividends paid out.
Dechra Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 108.4 M | |
| Quarterly Earnings Growth Y O Y | -0.458 | |
| Forward Price Earnings | 24.6914 | |
| Retained Earnings | 164 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |